Advantage For Synergy’s Plecanatide Over Rival Linzess Holds Up In IBS-C
Executive Summary
Plecanatide met the primary endpoint in first Phase III trial in irritable bowel syndrome with constipation, with less incidence of diarrhea than seen in Linzess trials. Synergy is awaiting approval in chronic idiopathic constipation and appears on pace to file an sNDA in IBS-C during the first quarter.
You may also be interested in...
Keeping Track: Shutdown Edition
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid
The latest drug development news and highlights from our FDA Performance Tracker.